Meeting News

Clinical scores predict risks for liver disease after isolated heart transplant

October 19, 2019
CHICAGO — Researchers determined clinical scores that assessed short-term risks for liver disease associated with isolated heart…

Meeting News

NASPGHAN 2019 chronic liver disease symposium provides update for GIs

October 16, 2019
CHICAGO — During this year’s North American Society for Pediatric Gastroenterology, Hepatology & Nutrition annual meeting, Mercedes

In the Journals

Egrifta reduces hepatic fat fraction in patients with NAFLD, HIV

October 14, 2019
Treatment with Egrifta demonstrated a greater reduction in hepatic fat fraction compared with placebo among patients with nonalcoholic fatty liver…

In the Journals

Liver fat changes unreliable for some histological predictions

October 11, 2019
Changes in liver fat can predict changes in steatosis but not other liver histological parameters like improvements in nonalcoholic fatty liver…

In the Journals

Consuming dietary fiber may reduce NAFLD risk among multiple ethnicities

October 9, 2019
Researchers found that while consumption of red and processed meat, poultry, and cholesterol correlated with nonalcoholic fatty liver disease…

Axcella completes enrollment in metabolic modulator trial for NAFLD

October 9, 2019
Investigators have completed trial enrollment for two novel compositions of endogenous metabolic modulators under evaluation as interventions to…

NGM Bio FGF19 therapy reduces liver fat in patients with NASH-fibrosis

October 7, 2019
NGM Bio announced positive interim results from ongoing study of aldafermin, an engineered version of human fibroblast growth factor 19 that…

Saroglitazar magnesium lowers ALT, hepatic fat in NAFLD

October 4, 2019
Results from the EVIDENCES IV trial showed that saroglitazar magnesium achieved its primary endpoint of reduced alanine aminotransferase in patients…

In the Journals

Quantification of key parameters accurately stages fibrosis in NAFLD

October 3, 2019
Dual-photon microscopy automated quantification of fibrosis-related parameters provided accurate assessments of fibrosis in patients with…

FXR candidate for NASH reduces alanine transaminase, liver fat

September 30, 2019
Enanta Pharmaceuticals announced positive results in alanine aminotransferase and liver fat content reduction from its current trial of EDP-305, a…

Aramchol moves into late-stage trial for NASH with fibrosis

September 27, 2019
Galmed Pharmaceuticals announced the initiation of a late-stage clinical trial to evaluate Aramchol for the treatment of nonalcoholic steatohepatitis…

In the Journals

Novel liver-targeted insulin comparable to insulin lispro in type 1 diabetes

September 25, 2019
Adults with type 1 diabetes assigned to a mealtime, liver-targeted insulin using hepatocyte-directed vesicle technology for 6 months experienced a…

In the Journals

NAFLD in children linked to lower bone mineral density

September 24, 2019
Researchers identified a link between the presence and severity of nonalcoholic fatty liver disease in children with reduced whole-body bone mineral…

In the Journals

Many European countries lack an informed health response to NAFLD

September 23, 2019
Recently published data reveal an inadequate public health response to nonalcoholic fatty liver disease in European countries, according to a study…

Healio Hot Topic

Spotting NASH Starts With Simple Calculations

Healio Gastroenterology, September 2019
Monica Tincopa, MD, MSc
Approximately 30% of Americans have fatty liver, but only a small proportion have progressed to nonalcoholic steatohepatitis. One of the…

Healio Hot Topic

Q&A: NASH Intervention Requires Mutual Learning Between Specialties

Healio Gastroenterology, September 2019
Specialists from all medical fields have become more aware over the last few decades about how one disease can feed the development of others and…

Healio Hot Topic

Coming Soon: NASH Treatment Approaching the Horizon

Healio Gastroenterology, September 2019
Stephen A. Harrison, MD
Nonalcoholic steatohepatitis is an increasingly common cause of cirrhosis, hepatocellular carcinoma and liver-related mortality. Along its…

Poxel NASH candidate moves into phase 1b

September 17, 2019
Poxel SA announced the initiation of a phase 1b trial designed to investigate PXL065 for the treatment of nonalcoholic steatohepatitis in patients…

Obesity in Liver Disease: 6 reports on comorbid overlap

September 13, 2019
The negative effects of obesity on overall health have been well-established along with the increasing rates throughout both the U.S. and…

Revita DMR improves metabolic profile in comorbid NAFLD, diabetes

September 10, 2019
Fractyl Laboratories announced positive topline results from the phase 2 trial of Revita duodenal mucosal resurfacing, or DMR, a minimally invasive…